Test Price
2,800 AED✅ Home Collection Available
CLDN14 Gene Autosomal Recessive Deafness Type 29 (DFNB29) Genetic Test in UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced NGS test deciphers the complete coding sequence of the CLDN14 gene linked to autosomal recessive nonsyndromic deafness DFNB29, delivering precise diagnostic and carrier information. The analysis covers all coding exons and flanking intronic regions to detect pathogenic variants, including deep intronic splice-site alterations that may be missed by traditional methods.
Pre-Test Requirements: Provide a detailed family and clinical history of hearing loss. A genetic counseling session to draw a pedigree is recommended. No special dietary restrictions are required prior to sample collection.
| Feature | Our CLDN14 NGS Test | Closest Alternative (Traditional Sanger) |
|---|---|---|
| Methodology | Next Generation Sequencing (NGS) – full gene coverage | Sanger sequencing of selected exons |
| Analytical Sensitivity | 99.9% (detects mosaicism, deep intronic variants) | ~95% (limited to targeted regions) |
| Turnaround Time | 3-4 Weeks | 6-8 Weeks |
| Comprehensiveness | All coding/non-coding pathogenic variants | Only pre-designed primer targets |
| Accreditation | ISO 9001:2015 Certified Lab | Varies |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (DHA Registration ID: 9294403), Consultant Medical Genetics, emphasizes: “A definitive molecular diagnosis of DFNB29 through CLDN14 sequencing empowers patients and families with accurate recurrence risk counseling. This test should always be paired with a comprehensive audiological evaluation and pre-test genetic counseling to ensure informed consent. A negative result does not exclude other genetic causes of hearing loss.”
⚠️ Safety Exclusion & Red Flags
- Not suitable for acquired (non-genetic) hearing loss due to infection, trauma, or ototoxicity without prior genetic indication.
- Requires prior genetic counseling to obtain informed consent, especially for minors under UAE Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Red flags: Sudden sensorineural hearing loss or active ear infection require immediate ENT evaluation before sample collection.
⚠️ Medication Advisory
Do not discontinue any prescribed medication without consulting your doctor.
Patient FAQ & Clinical Guidance
1. What is the CLDN14 gene deafness test and how does it help?
This NGS test analyzes the entire CLDN14 gene to identify disease-causing variants, providing a definitive diagnosis of DFNB29 and guiding reproductive options.
2. How is the sample collected and is home collection available?
We dispatch a certified phlebotomist to your home for venous blood or finger prick onto an FTA card, all under temperature-controlled cold-chain conditions. VIP Mobile Phlebotomy is available daily from 8 AM to 11 PM.
3. What is the turnaround time and what do I do after receiving results?
Results are delivered within 3-4 weeks, followed by a complimentary telephonic clinical guidance session to interpret the report and connect you with a genetic counselor.
4. Is this test covered by insurance in the UAE?
Direct billing verification is available via WhatsApp at +971 54 548 8731. Coverage varies by provider; we recommend confirming with your insurer prior to testing.
5. Can this test be performed on children?
Yes, with appropriate genetic counseling and parental informed consent in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
UAE Regulatory & Data Privacy Adherence
This test adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for all patient data handling and storage. Health data processing complies with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and informed consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Laboratory services are ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) under DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | CLDN14 Gene Autosomal Recessive Deafness Type 29 (DFNB29) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3-4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) or FTA Card |
| Methodology Used | Next Generation Sequencing (NGS) – Full Gene Coverage including coding exons and flanking intronic regions |
| ICD-10-CM Code | H90.3 (Sensorineural hearing loss, bilateral) |
| LOINC Code | 82272-3 (CLDN14 gene full sequencing by NGS) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians